217 related articles for article (PubMed ID: 9384246)
1. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
3. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
6. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
7. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.
Kearn CS; Greenberg MJ; DiCamelli R; Kurzawa K; Hillard CJ
J Neurochem; 1999 Jun; 72(6):2379-87. PubMed ID: 10349847
[TBL] [Abstract][Full Text] [Related]
8. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum.
Cadogan AK; Alexander SP; Boyd EA; Kendall DA
J Neurochem; 1997 Sep; 69(3):1131-7. PubMed ID: 9282935
[TBL] [Abstract][Full Text] [Related]
9. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
[TBL] [Abstract][Full Text] [Related]
10. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
12. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
14. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
Petitet F; Jeantaud B; Capet M; Doble A
Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
[TBL] [Abstract][Full Text] [Related]
15. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
18. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice.
Basavarajappa BS; Hungund BL
J Neurosci Res; 2001 May; 64(4):429-36. PubMed ID: 11340650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]